SCHEDULE: Erik Otto Discloses 6.3% Stake in Chemomab Therapeutics

Erik Otto has reported a 6.3% beneficial ownership stake in Chemomab Therapeutics Ltd., holding 385,000 American Depository Shares.

Summary

• Erik Otto, a Canadian citizen, has filed an Amendment No. 2 to Schedule 13G regarding his beneficial ownership in Chemomab Therapeutics Ltd.
• Otto beneficially owns 385,000 American Depository Shares (ADSs) of Chemomab Therapeutics Ltd.
• This ownership represents 6.3% of the company's outstanding ADSs.
• The percentage is calculated based on 6,155,117 ADSs outstanding as of November 20th, 2025, as provided by the Issuer.
• Otto holds sole voting and sole dispositive power over all 385,000 shares.
• The securities were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant individual investor has disclosed a substantial stake, which can imply confidence in the company's future.

Positives

• A significant individual investor, Erik Otto, holds a 6.3% stake, potentially indicating confidence in Chemomab Therapeutics Ltd.
• The investor has sole voting and dispositive power over the shares, suggesting direct control over this block.

Industry Context

StockSavvy.ai notes that beneficial ownership filings like this Schedule 13G provide transparency into significant shareholder positions, which can sometimes signal investor confidence or strategic interest in a company within the biotechnology sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant individual investor holding a 6.3% stake may instill confidence among existing and potential shareholders.

Key Dates

Keywords

Chemomab Therapeutics, CMBP, Erik Otto, Schedule 13G, Beneficial Ownership, ADS, American Depository Shares, Biotechnology, Pharmaceuticals, Investor Filing